George Abraham to Antiviral Agents
This is a "connection" page, showing publications George Abraham has written about Antiviral Agents.
Connection Strength
2.989
-
Abraham GM, Spooner LM. Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease. Clin Infect Dis. 2018 01 18; 66(3):464-474.
Score: 0.478
-
Spooner LM, Abraham GM. Sustained virological response in a treatment-experienced patient with hepatitis C virus genotype 6 infection: Follow-up on a reported case. Am J Health Syst Pharm. 2017 04 15; 74(8):555.
Score: 0.453
-
Spooner LM, Abraham GM. Retreatment of a treatment-experienced patient with genotype 6 hepatitis C virus infection: follow-up on a reported case. Am J Health Syst Pharm. 2015 Jan 01; 72(1):14-6.
Score: 0.387
-
Abraham GM, Spooner LM. Sofosbuvir in the treatment of chronic hepatitis C: new dog, new tricks. Clin Infect Dis. 2014 Aug 01; 59(3):411-5.
Score: 0.368
-
Gammal RS, Spooner LM, Abraham GM. Failed triple therapy in a treatment-experienced patient with genotype 6 hepatitis C infection. Am J Health Syst Pharm. 2014 Feb 01; 71(3):204-8.
Score: 0.363
-
Qaseem A, Yost J, Miller MC, Andrews R, Jokela JA, Forciea MA, Abraham GM, Humphrey LL, Lee RA, Tschanz MP, Etxeandia-Ikobaltzeta I, Harrod C, Shamliyan T, Umana K. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1). Ann Intern Med. 2023 01; 176(1):115-124.
Score: 0.167
-
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Miller MC, Forciea MA, Humphrey LL. Update Alert 2: Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 12; 174(12):W116-W117.
Score: 0.155
-
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL, Centor RM, Andrews R, Haeme R. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2021 05; 174(5):673-679.
Score: 0.148
-
Abraham GM, Morton JB, Saravolatz LD. Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza. Clin Infect Dis. 2020 10 23; 71(7):1790-1794.
Score: 0.145
-
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL, Centor RM, Andrews R, Haeme R, Kansagara DL, Marcucci M. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1). Ann Intern Med. 2021 02; 174(2):229-236.
Score: 0.144
-
Sterling RK, Kuo A, Rustgi VK, Sulkowski MS, Stewart TG, Fenkel JM, El-Genaidi H, Mah'moud MA, Abraham GM, Stewart PW, Akushevich L, Nelson DR, Fried MW, Di Bisceglie AM. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharmacol Ther. 2015 Apr; 41(7):671-85.
Score: 0.097
-
Qaseem A, Yost J, Abraham GM, Andrews R, Jokela JA, Miller MC, Humphrey LL, Dunn A, Haeme R, Lee R, Saini SD, Tschanz CMP, Etxeandia-Ikobaltzeta I, Harrod C, Shamliyan T, Umana K. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2023 10; 176(10):1396-1404.
Score: 0.044
-
Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, Abraham GM, Jokela JA, Forciea MA, Miller MC, Humphrey LL. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2, Update Alert 3). Ann Intern Med. 2022 05; 175(5):W55-W57.
Score: 0.040